孟鲁司特联合盐酸西替利嗪治疗儿童咳嗽变异性哮喘效果观察

The effects of montelukast combined cetirizine hydrochloride on treatment of children with cough variant asthma

目的观察口服白三烯调节剂孟鲁司特钠(LTM)联合盐酸西替利嗪治疗儿童咳嗽变异性哮喘(CVA)的疗效。方法将84例CVA患儿随机分为LTM组(42例)和ICS组(42例)。LTM组患儿每晚口服孟鲁司特钠2.5～5mg维持治疗,同时联合盐酸西替利嗪滴剂2～5mg,每日1次;后者咳嗽时使用,咳嗽消失后停药。ICS组患儿通过定量气雾剂+储雾罐规律吸入布地奈德200～400μg/d维持治疗,治疗时间3个月,并随访3个月观察各自复发情况。结果 LTM组平均止咳天数为(13±9)d,ICS组平均止咳天数为(14±9)d,两组间比较差异无统计学意义(Z=1.12,P=0.25)。两组治疗3个月后随访3个月,LTM组咳嗽复发的比率(33.3%)明显高于ICS组(7.1%,χ2=8.92,P<0.01)。结论 LTM联合盐酸西替利嗪治疗CVA疗效明确,副作用少,依从性好,与吸入糖皮质激素疗效相当,值得临床推广,但远期疗效不如后者。

Objective To observe and compare the effects of oral leukotriene modifier montelukast sodium（ltm） combined with cetirzine hydrochloride and inhaled corticosteroids（ICS） treatment of children with cough variant asthma（CVA）.Methods 84 cases were randomly divided into LTM group（42 cases） and the ICS group（42 cases）.LTM group was treated with oral montelukast combined with cetirzine hydrochloride.The ICS group was treated with budesonide.Results The time of cough of LTM group and ICS group were 13±9d and 14±9d（P〉0.05）.The cough recurrence rate of LTM group and ICS group were 33.3% and 7.1%（χ2=8.92,P〈0.01）.Conclusion It is effective and safe to treat children with cough variant asthma with LTM combined cetirizine hydrochloride.